Other authors argue that the lack of correlation between tumor PD-L1 (determined by immunohistochemical analysis) and sPD-L1 indicates that different immune cells may be upregulating PD-L1 expression as a response to pro-inflammatory cytokines such as IFNγ and IL6, in the context of ICI immunotherapy [37]. The gene discussed is SPDL1; the disease is neoplasm.